Renhuang CEO Li Shaoming On Growing Traditional Chinese Medicine Business In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Renhuang CEO Li Shaoming recently spoke with PharmAsia News' Shanghai bureau about the Chinese TCM market, the impact of current government policies and the effect of the Sichuan earthquake on drug makers. Founded in 1996 in Harbin, Heilongjiang province, Renhuang Pharmaceuticals provides three major product lines, including Siberian ginseng-based natural medicinal products, biopharmaceutical products and traditional Chinese medicines. In September 2006, Renhuang became a public company in the United States through a reverse merger, and it is currently traded on NASDAQ as OTCBB.